3[1]SpiegelmanBM.adpogenic regulator and thiazolidinedione receptor.Diabetes.1998,47,507-514.
4[1]Groop LC.lnsulin resistance:the fundamental trigger of type 2 diabetes.Diabetes Obes Metab,1999,1(suppll):1-7.
5[2]Haffner SM,D' Agostino R Jr.Mykkanenl,insulin sensitivity in subjects with type 2 diabetes.relationship to cardiovascular risk fuctors; the insulin Resistance Atherosclerosis Study.Diabetes Care.1999,2(4):562-568.
6[4]Digby JE.Montague CT,stewter CP,et al.Thiazolidinedione exposure increases the expression of uncoupling protein l in Cultured human preadipocytes.Diabetes,1998,47(1):138-141.
7[5]Banerji M,lebovitz HE,Dugbartey M.Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus.Diabetes,2001,50(2):90.
8Pavo I,Jermendy G,Varkonyi TT,et al.Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes[J].J Clin Endoerinol Metab,2003,88(4):1637-1645.
9Raskin P,Rendell M,Riddle MC,et al.A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes[J].Diabetes Care,2001,24(7):1226-1232.
10Hallsten K,Virtanen KA,Lonnqvist F,et al.Rosiglitazone but not metformin enchances insulin-and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes[J].Diabetes,2002,51(12):3479-3485.
